It is also worth noting that the same type of analysis done in the dialysis patient population of the corresponding Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Dialysis (ASCEND-D) trial was barely statistically significant [ 84 ].
← all excerpts
Growing concerns about using hypoxia-inducible factor prolyl hydroxylase inhibitors for the treatment of renal anemia.
1
—
—